Share on StockTwits

Evotec AG (NASDAQ:EVTC) has been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the stock, AnalystRatingsNetwork.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $26.50.

Shares of Evotec AG (NASDAQ:EVTC) opened at 23.08 on Wednesday. Evotec AG has a 52 week low of $20.64 and a 52 week high of $26.33. The stock’s 50-day moving average is $24.12 and its 200-day moving average is $24.24. The company’s market cap is $1.809 billion.

Evotec AG (NASDAQ:EVTC) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.39 by $0.01. The company had revenue of $87.20 million for the quarter, compared to the consensus estimate of $91.26 million. The company’s quarterly revenue was down .1% on a year-over-year basis. Analysts expect that Evotec AG will post $1.68 EPS for the current fiscal year.

Separately, analysts at Goldman Sachs initiated coverage on shares of Evotec AG in a research note on Tuesday, July 8th. They set a “neutral” rating on the stock.

Evotec AG is a Germany-based parent company of the Evotec group, which is engaged in drug discovery and development company focused on providing integrated drug discovery services and alliances to the pharmaceutical and biotechnology industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.